Mustang Bio (MBIO) Projected to Release Earnings on Tuesday

Mustang Bio (NASDAQ:MBIO) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to announce earnings of ($140.00) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 7:00 AM ET.

Mustang Bio (NASDAQ:MBIO) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($140.00) by $139.84.

Mustang Bio Trading Down 1.8%

NASDAQ MBIO opened at $0.59 on Tuesday. The firm has a market cap of $4.47 million, a price-to-earnings ratio of -1.31 and a beta of 2.06. The company has a 50 day moving average of $0.66 and a 200-day moving average of $0.76. Mustang Bio has a 1-year low of $0.53 and a 1-year high of $1.88.

Hedge Funds Weigh In On Mustang Bio

A hedge fund recently bought a new stake in Mustang Bio stock. DRW Securities LLC acquired a new stake in Mustang Bio, Inc. (NASDAQ:MBIO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned about 1.01% of Mustang Bio as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 9.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mustang Bio in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.